An alternative dosing strategy for ropeginterferon alfa-2b ...

January 19, 2023

Ropeginterferon alfa-2b, approved for polycythemia vera (PV) treatment, shows safety and efficacy in clinical trials. Emerging studies suggest higher initial doses and rapid titration may enhance tolerability and efficacy. Ongoing research explores its application in myeloproliferative neoplasms, aiming to optimize dosing for improved patient outcomes.

Related Clinical Trials

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics Study of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects

A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU

Dose Finding Study of Pegylated-P-Interferon-alpha-2b(P1101) in Treatment-Naive Subjects With Hepatitis C Virus Genotype 1 Infection

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients

Ropeginterferon Alfa 2b for Early Myelofibrosis

Single Dose Escalation Study of P1101 in Healthy Adult Male Subjects

Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply

P1101 in Treating Patients With Myelofibrosis

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

Reference News

pmc.ncbi.nlm.nih.gov

An alternative dosing strategy for ropeginterferon alfa-2b ...